Zobrazeno 1 - 10
of 2 026
pro vyhledávání: '"Complement inhibitor"'
Autor:
Masanori Matsumoto, Akihiko Shimono, Jun Yokosawa, Keiichiro Hirose, Edward Wang, Shoichi Maruyama
Publikováno v:
Thrombosis Journal, Vol 22, Iss 1, Pp 1-11 (2024)
Abstract Background Atypical hemolytic uremic syndrome (aHUS) is a rare disease with poor outcomes when untreated, in which ravulizumab or eculizumab are the standard of care where available. It has been proposed to regularly monitor platelet counts
Externí odkaz:
https://doaj.org/article/3634c59e40ed4b91a154deff419fb061
Publikováno v:
Journal of Translational Medicine, Vol 22, Iss 1, Pp 1-13 (2024)
Abstract Numerous clinical trials for myasthenia gravis (MG) treatment have been conducted recently, with satisfactory cognitive and clinical results. However, due to the limited evidence for direct comparison of the safety and effectiveness of vario
Externí odkaz:
https://doaj.org/article/635760d57f0e4a8d9c8b35c4c7674581
Autor:
Julien Dereme, Matthew Goodyer, David Baud, Lorenzo Alberio, Francesco Grandoni, Mathilde Gavillet
Publikováno v:
eJHaem, Vol 5, Iss 5, Pp 1048-1052 (2024)
Abstract Paroxysmal nocturnal hemoglobinuria (PNH) is a rare hematological disorder characterized by the absence of complement regulatory proteins on the surface of erythrocytes, leading to intravascular hemolysis and thrombosis. Managing PNH during
Externí odkaz:
https://doaj.org/article/0593056ed6404130bbccd229a9dbf798
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
Externí odkaz:
https://doaj.org/article/3332515a4d1b4249bc3fba882965296d
Publikováno v:
Annals of Medicine, Vol 55, Iss 2 (2023)
AbstractObjective Paroxysmal nocturnal hemoglobinuria (PNH) is a rare acquired disease characterized by chronic complement-mediated hemolysis. The concentrated outbreak of coronavirus disease 2019 (COVID-19) in China after 6 December 2022, provided a
Externí odkaz:
https://doaj.org/article/26fb8bdc7dc64584b1d4861780fd9cb6
Autor:
Attila Szvetnik, Vilmos Tubak
Publikováno v:
Biomedicines, Vol 12, Iss 3, p 646 (2024)
Therapeutic recombinant proteins are powerful tools used for the treatment of many detrimental diseases such as diabetes, cancer, multiple sclerosis, rheumatoid arthritis, hepatitis, and many more. Their importance in disease therapy is growing over
Externí odkaz:
https://doaj.org/article/4a2a5f43a82b40e69947089255940f99
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Huiru Chen, Youjia Qiu, Ziqian Yin, Zilan Wang, Yanbing Tang, Hanyu Ni, Jiaye Lu, Zhouqing Chen, Yan Kong, Zhong Wang
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
BackgroundA series of clinical trials support the effectiveness of monoclonal antibodies for generalized myasthenia gravis (MG) compared to the placebo, but the priority among drugs remains unclear. Therefore, we conduct a frequentist network meta-an
Externí odkaz:
https://doaj.org/article/a72bfca820864716940f3b2e67dba110
Autor:
Hui Yang, Xingxing Chai, Yuemin Gong, Xinyu Zhang, Lingling Wang, Xin Zhou, Xiaoyu Chen, Jinge Xu, Dan Xu, Guangsheng He, Jianyong Li
Publikováno v:
Immunity, Inflammation and Disease, Vol 11, Iss 8, Pp n/a-n/a (2023)
Abstract Introduction Paroxysmal nocturnal hemoglobinuria (PNH) is characterized by hemolytic anemia, bone marrow failure, thrombophilia. COVID‐19, caused by a novel severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) with many variant
Externí odkaz:
https://doaj.org/article/ae36e29327904027ad2fc035dc1cdfcf
Autor:
Lu Xing, Li-Yi Jia, Xiao-Ying Sun, Meng Guo, Jie Jin, Yin-Di Wang, Ling Huang, Yi-Heng Li, Zhong-Jing He, Rong Li, Hui-Ling Cao
Publikováno v:
Guoji Yanke Zazhi, Vol 22, Iss 5, Pp 803-808 (2022)
Age-related macular degeneration(ARMD)is one of the main causes of irreversible visual impairment in the middle-aged and elderly people, which severely impacts the patient's life quality and poses a substantial health economic burden on society. Ther
Externí odkaz:
https://doaj.org/article/33a5272385b04ef291479aeee9a7eaca